Klow

Where the name "Klow" comes from

"Klow" is a community name for the Glow combination with two additions: KPV and larazotide. The name reads as an initialism of its own parts, K for KPV, L for larazotide, and the rest of the Glow components after it. That appears to be the whole of its documented origin. Peptide Health Lab neither coined the name nor endorses it.

No published paper proposes this combination, defines it, or tests it. As with every community stack name, the component list is not stable between sources, and what is described here is the version the term most often refers to. The surrounding dynamic is described plainly in a 2026 narrative review of peptides in sports medicine: demand for these compounds has outpaced the evidence base by a wide margin, and social media amplifies the placebo response that makes an untested combination feel like it worked.^[10]

The reason Klow exists as a separate name from Glow is that it is pointed at a different idea. Glow is aimed at skin. Klow is aimed at a story about barrier and inflammation that spans gut and skin at once. Whether that story is supported is the subject of the rest of this page.

What's in it and why people combine them

KPV is the addition that defines the name. It is the three-residue carboxy-terminal tail of α-melanocyte-stimulating hormone, and it is the component with the most internally coherent animal literature in this combination. In two established mouse models of inflammatory bowel disease, dextran sodium sulfate colitis and CD45RB-high transfer colitis, KPV produced earlier recovery, significantly greater weight regain, fewer inflammatory infiltrates on histology, and significantly reduced colonic myeloperoxidase activity. It worked in animals with a non-functional melanocortin-1 receptor, which is why the anti-inflammatory effect is described as at least partly independent of that receptor.^[1] A later study loaded KPV into hyaluronic-acid-functionalized nanoparticles delivered orally in a hydrogel and reported accelerated mucosal healing and reduced TNF-α, which is a result about a delivery system as much as about the peptide.^[2] On the skin side, KPV protected cultured human keratinocytes and a three-dimensional skin construct from particulate-matter-induced inflammation and apoptosis by suppressing reactive oxygen species.^[3]

Larazotide is named here and not reviewed here. It has no page on this site. Peptide Health Lab has not evaluated it, takes no position on it, and presents no evidence about it on this page. Naming a component so a reader knows what the community term refers to is the entire purpose it serves here; describing what it does would be reviewing a compound this property has not reviewed.

The three Glow components come along unchanged. GHK-Cu contributes the matrix-signalling story, resting on stimulation of collagen synthesis in cultured fibroblasts at picomolar to nanomolar concentrations.^[5] BPC-157 contributes rodent wound and mucosal healing, including accelerated closure in an alkali-burn skin model.^[7] TB-500 contributes the cell-migration and angiogenesis story that belongs, in the human trials, to full-length thymosin β4 rather than to the fragment.^[8]

A 2025 review of tripeptides in wound healing covers GHK-based formulations and KPV in the same article, but as separate lines of work, in separate sections, with no combined study to report.^[4] That is the honest shape of the rationale: several plausible mechanisms, assembled by a reader rather than demonstrated by a trial.

What the evidence says about the combination

No published study has evaluated this combination. Not the five components together, not the four peptide components without larazotide, not any three of them. Searching the literature for the components in combination returns reviews that discuss them individually and returns no study that administered them together.^[4]

The one published test of additivity involving any two of these components is a 2026 rat study in which thirty-two animals underwent Achilles tendon transection and repair and were randomized to control, BPC-157, TB-500, or the two combined for four weeks. TB-500 alone reached significance on maximum load to failure and on histopathological scoring; the combined arm conferred no additional benefit over either agent alone. The authors propose that the two may converge on shared downstream pathways and note the hypothesis is untested.^[9]

That is a tendon model, in rats, covering two of five components. Its answer to "does stacking these help more than one alone" was no. The combination claim on this page is graded anecdotal for the straightforward reason that the combination has never been studied.

Where the evidence is weak

Every component's strongest result is in a different system. KPV's is in mouse colon. GHK-Cu's is in cultured fibroblasts and keratinocytes. BPC-157's is in rat skin and gut. Thymosin β4's is in human chronic ulcers, and that work used the parent protein rather than the fragment. Assembling five components whose evidence lives in five different systems does not produce evidence for a combined effect in a person; it produces five separate literatures sharing a name.

The human evidence that exists is either negative or about a different molecule. The randomized human trial of topical GHK-Cu found no significant difference from control on resolution of erythema, on wrinkles, or on overall skin quality by objective assessment, with only the patients' own satisfaction questionnaire separating.^[6] That is the signature of a placebo-sensitive outcome. The venous-ulcer programme is real randomized human evidence, but it studied the full 43-residue thymosin β4 protein in a pharmaceutical topical formulation, and describes its own efficacy findings as suggestive.^[8]

KPV has no human trial at all. The rodent colitis work is consistent and mechanistically coherent, and it stops at rodents. Nothing in the published record establishes an effect, a safety profile, or an exposure level for KPV in a person.^[1]

A component nobody here has reviewed is still in the mixture. A page that names larazotide without reviewing it is being accurate about what the community term includes; it is not telling a reader that the component is understood, characterized, or accounted for in anything above. It is not.

Interactions between five simultaneous unapproved compounds are entirely unstudied. Nothing in the published record addresses what any of these components do in the presence of the others, or in the presence of prescribed medication.^[10]

Questions to bring to a provider

The productive version of this conversation is not "is Klow better than Glow." It is "here is the symptom I actually want addressed, and here is what has been shown to address it."

• If the target is a gut symptom, what is the working diagnosis, and what does the standard-of-care evidence offer for it specifically?
• Given that the KPV literature is entirely rodent, what would have to be true for it to be worth considering ahead of an evaluated option?^[1]
• How should a component that has not been reviewed, characterized, or graded anywhere on this page factor into a decision about the mixture that contains it?
• What interactions with current medication would a clinician want to think about before anything in this combination is considered?^[10]
• Which objective measure would show whether anything changed? A symptom score at a fixed interval, an inflammatory marker, standardized photography?

Anti-doping status

Two of the components named in this combination are prohibited in tested sport at all times, in and out of competition, under the World Anti-Doping Agency Prohibited List in force for 2026:

• BPC-157: section S0, non-approved substances. S0 covers any pharmacological substance not addressed by another section of the List and with no current approval by any governmental regulatory health authority for human therapeutic use; BPC-157 is named there as an example. Substances in this class are Specified Substances.
• TB-500: section S2.3, growth factors and growth factor modulators, where the List names "thymosin-β4 and its derivatives" and gives TB-500 as the example. S2 substances are non-Specified Substances, which carries different sanctioning consequences from S0.

KPV, GHK-Cu, and larazotide are not named anywhere on the 2026 List, and that is not the same as being permitted. S0 is written as a criterion rather than as a closed catalogue: it reaches any pharmacological substance without current approval for human therapeutic use that is not addressed by another section. A tested athlete should treat an unapproved injectable as a question for their national anti-doping organization rather than as a settled absence.

These statuses were read from the published Prohibited List itself rather than from the research literature, because the research literature has stated them wrongly: a 2025 review of BPC-157 asserts in its abstract that the compound was banned only temporarily and is not currently listed, which is false, and that sentence still circulates. A review is a source for what the literature shows and never a source for what a regulator has done.^[10] Sections renumber between annual editions, so a competing athlete should confirm the current year's list rather than this page.